[Question of the European Agency of Drugs (EMEA): interaction between drotrecogin alfa (activated) and heparin in prophylactic dose].
Meshaka
P
P
Laboratoire Lilly, 13, rue Pagès, 92158 Suresnes cedex, France.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D004347:Drug Interactions; D005060:Europe; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D006077:Government Agencies; D006493:Heparin / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D011486:Protein C / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology*; D012044:Regression Analysis; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005343:Fibrinolytic Agents; D011486:Protein C; D011994:Recombinant Proteins; D006493:Heparin; C421124:drotrecogin alfa activated